Surgery, Radiation therapy, Pancreaticoduodenectomy, Pancreatic cancer and Pancreatic disease are his primary areas of study. His Surgery research integrates issues from Internal medicine and Adenocarcinoma. His Adenocarcinoma study combines topics in areas such as Neoadjuvant therapy, Survival analysis and Oncology.
His studies deal with areas such as Gemcitabine, Primary tumor and Performance status as well as Radiation therapy. His Pancreaticoduodenectomy research includes elements of Clinical pathway, Perioperative, Retrospective cohort study and Vein. His research in Pancreatic cancer intersects with topics in Preoperative care, Radiology and General surgery.
Peter W.T. Pisters mainly focuses on Surgery, Internal medicine, Radiation therapy, Cancer and Pancreaticoduodenectomy. His Surgery study combines topics from a wide range of disciplines, such as Radiology and Sarcoma. His work deals with themes such as Gastroenterology and Oncology, which intersect with Internal medicine.
His Cancer research is multidisciplinary, incorporating elements of Stage, Proportional hazards model and Lymph node. His Pancreaticoduodenectomy research is multidisciplinary, incorporating perspectives in Superior mesenteric artery, Perioperative, Capecitabine and Vein. In his study, Carcinoma is inextricably linked to Pancreatectomy, which falls within the broad field of Pancreatic cancer.
Peter W.T. Pisters mainly investigates Internal medicine, Oncology, Neoadjuvant therapy, Pancreaticoduodenectomy and Pancreatic cancer. His Internal medicine study typically links adjacent topics like Gastroenterology. Peter W.T. Pisters has included themes like Superior mesenteric artery, Surgery, Carcinoma, Neoplasm Recurrence and Chemoradiotherapy in his Neoadjuvant therapy study.
Peter W.T. Pisters interconnects Colorectal cancer and Radiology in the investigation of issues within Surgery. His Pancreatic cancer study improves the overall literature in Cancer. His research in Lymph node focuses on subjects like Lymph, which are connected to Radiation therapy.
Peter W.T. Pisters spends much of his time researching Surgery, Neoadjuvant therapy, Pancreatic cancer, Internal medicine and Pancreaticoduodenectomy. His Surgery research incorporates elements of Open Resection, Colorectal cancer and GiST. The study incorporates disciplines such as Chemoradiotherapy, Pancreatectomy and Adenocarcinoma in addition to Neoadjuvant therapy.
Peter W.T. Pisters usually deals with Pancreatic cancer and limits it to topics linked to Gastroenterology and Fluorouracil and Dose fractionation. Peter W.T. Pisters works on Internal medicine which deals in particular with Chemotherapy. Vein and Survival rate is closely connected to Radiology in his research, which is encompassed under the umbrella topic of Pancreaticoduodenectomy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki.
The Lancet (2009)
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial
James Fleshman;Megan Branda;Daniel J. Sargent;Anne Marie Boller.
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong.
Annals of Surgical Oncology (2006)
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun.
Journal of The American College of Surgeons (2008)
Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun.
Journal of Clinical Oncology (2008)
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.
F. R. Spitz;J. L. Abbruzzese;Jeffrey E Lee;Peter W Pisters.
Journal of Clinical Oncology (1997)
Pancreaticoduodenectomy with vascular resection: margin status and survival duration
Jennifer F. Tseng;Chandrajit P. Raut;Jeffrey E. Lee;Peter W.T. Pisters.
Journal of Gastrointestinal Surgery (2004)
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
Chandrajit P. Raut;Jennifer F. Tseng;Jennifer F. Tseng;Charlotte C. Sun;Huamin Wang.
Annals of Surgery (2007)
Desmoid Tumor: Prognostic Factors and Outcome After Surgery, Radiation Therapy, or Combined Surgery and Radiation Therapy
Matthew T. Ballo;Gunar K. Zagars;Alan Pollack;Peter W.T. Pisters.
Journal of Clinical Oncology (1999)
Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
Gauri R. Varadhachary;Robert A. Wolff;Christopher H. Crane;Charlotte C. Sun.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: